FDA Exemption for Genetic-Profile Drugs Expands Right to Try

What it does

This bill expands the 'Right to Try' law to allow terminally ill or severely debilitated patients to access experimental individualized medical treatments (drugs or biologics tailored to a patient's unique genetic profile) without FDA approval, provided they have exhausted approved options and obtain physician certification and written informed consent. Manufacturers are permitted but not required to provide these treatments, and the treatments must be developed within facilities operating under federal human-subjects protections.

Why we flagged it

The bill's core function is to extend an existing compassionate-use exemption (Right to Try) to a new category of treatments — individualized genetic-profile-based drugs — while creating a regulatory pathway that bypasses standard FDA pre-market review. This is a deregulatory measure framed as patient access.

What the text implies

• Manufacturers are not required to provide treatments, so the 'right' is conditional on manufacturer discretion; patients have no enforceable claim to access.
• No post-treatment data collection or adverse-event reporting mandate is specified, creating a gap in real-world safety monitoring for novel individualized treatments.
• Physician certification requires only that the doctor is 'in good standing' and will not be directly compensated by the manufacturer — no requirement for expertise in genomic medicine or the specific treatment.
• The bill references 'eligible health care facility' as one operating under federal human-subjects protections (IRB oversight), but does not require IRB review of individual Right to Try requests, only facility-level compliance.
• Genetic-profile-based treatments are highly novel and patient-specific; the informed-consent standard may be difficult to meet when efficacy and safety data are sparse or nonexistent.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Terminally ill patients gain access to experimental treatments they could not otherwise obtain, a concrete benefit when approved options have failed. However, the bill creates a regulatory exemption with minimal safety oversight beyond physician certification and informed consent — no requirement for efficacy data, no post-treatment monitoring mandate, and no liability framework if the treatment harms the patient. The benefit is real but contingent on individual physician judgment and manufactur

Who stands to gain

• manufacturers of investigational individualized medical treatments
• genomic medicine companies
• personalized medicine developers

Named in the bill

FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Section 561B (Right to Try), Section 312.81 (life-threatening disease definition), Public Health Service Act Section 491, eligible health care facilities, investigational individualized medical treatments

Where it stands

1 cosponsor: 1 Republicans.

• Jun 8, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 8, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.